Provides preclinical cancer-drug studies and PDX data to pharmaceutical and biotechnology companies, offers cancer-research software to scientists, and develops oncology drugs.
10-K for FY2026, filed Jul 27, 2026Our research services utilize our research center to assist pharmaceutical and biotechnology companies with their drug development process.…View ↗
We offer access to certain PDX model data via licensing agreements. As our platform has been expanded over time with the collection of…View ↗
Our SaaS business is centered around our proprietary software platform and data tool, Lumin Bioinformatics ("Lumin"), which contains…View ↗
Drug Discovery and Development BusinessView ↗
Pharmaceutical and biotechnology companies pay fixed fees for research studies, generally invoiced on milestones as the work progresses. PDX data access is sold for a fixed fee upfront, while Lumin is sold by annual subscription.
10-K for FY2026, filed Jul 27, 2026The Company generally enters into contracts with customers to provide oncology services with payments based on fixed-fee arrangements. At…View ↗
The majority of the Company's revenue arrangements are service contracts that are completed within a year or less. There are a few…View ↗
The Company also enters into contracts to provide access to certain Patient Derived Xenograft ("PDX") model data via a license agreement…View ↗
Our SaaS business is centered around our proprietary software platform and data tool, Lumin Bioinformatics ("Lumin"), which contains…View ↗
10-K for FY2026, filed Jul 27, 2026
FY2026 revenue by product or service ↗$59.4M
10-K for FY2026, filed Jul 27, 2026
$59.4M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Pharmacology services
Recurring
10-K for FY2026, filed Jul 27, 2026 |
96%
FY2023: 94%
|
Pharmacology services, FY2026
$57.1M Sources
|
Recurring |
|
TOS data license revenue
Licensed
|
1.3% |
TOS data license revenue, FY2026
$764K Sources
|
Licensed |
|
Other TOS revenue
|
2.6%
FY2023: 5.7%
|
Other TOS revenue, FY2026
$1.5M Sources
|
Pharmaceutical and biotechnology companies buy research services directly through the company’s sales force and also license PDX data. Cancer research scientists are customers for Lumin software, which is sold by annual subscription.
10-K for FY2026, filed Jul 27, 2026Our sales and marketing efforts are dependent on a dedicated sales force of approximately 45 professionals that sell our services directly…View ↗
We offer access to certain PDX model data via licensing agreements. As our platform has been expanded over time with the collection of…View ↗
The sale of research services utilizing our innovative research platforms to biopharmaceutical companies The sale of PDX model data and…View ↗
Our SaaS business is centered around our proprietary software platform and data tool, Lumin Bioinformatics ("Lumin"), which contains…View ↗
10-K for FY2026, filed Jul 27, 2026
For the year ended April 30, 2026, one of our customers accounted for 10% or more of our total revenue, at 24%. For the year ended April…View ↗
No. It lost $1.2M in FY2026.
10-Q for Q1 FY2027, filed Sep 11, 2026
−$426KView ↗
10-Q for Q1 FY2027, filed Sep 11, 2026
Open tableView ↗
Growing. Revenue grew 21% in 4 years, from $49.1M in FY2022 to $59.4M in FY2026, about 5% a year.
Loading...